The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase I study evaluating NT-I7 (efineptakin alfa) following standard of care CD19 CAR-T in R/R LBCL
Zachary Crees, MD, Washington University School of Medicine, St. Louis, discusses a Phase I study (NCT05075603) evaluating the long-acting IL-7 cytokine NT-I7 (efineptakin alfa) administered after standard-of-care CD19 CAR T-cell therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Crees explains that NT-I7 was administered to enhance CAR T-cell expansion and persistence, with the hopes of improving response rates without increasing toxicity. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
